222 related articles for article (PubMed ID: 23772639)
1. Molecular characteristics of diffuse large B-cell lymphoma in human immunodeficiency virus-infected and -uninfected patients in the pre-highly active antiretroviral therapy and pre-rituximab era.
Morton LM; Kim CJ; Weiss LM; Bhatia K; Cockburn M; Hawes D; Wang SS; Chang C; Altekruse SF; Engels EA; Cozen W
Leuk Lymphoma; 2014 Mar; 55(3):551-7. PubMed ID: 23772639
[TBL] [Abstract][Full Text] [Related]
2. Diffuse large B-cell lymphoma in a South African cohort with a high HIV prevalence: an analysis by cell-of-origin, Epstein-Barr virus infection and survival.
Cassim S; Antel K; Chetty DR; Oosthuizen J; Opie J; Mohamed Z; Verburgh E
Pathology; 2020 Jun; 52(4):453-459. PubMed ID: 32305135
[TBL] [Abstract][Full Text] [Related]
3. Impact of Double Expression of C-MYC/BCL2 Protein and Cell of Origin Subtypes on the Outcome among Patients with Diffuse Large B-Cell Lymphoma: a Single Asian Center Experience.
Teoh CS; Lee SY; Chiang SK; Chew TK; Goh AS
Asian Pac J Cancer Prev; 2018 May; 19(5):1229-1236. PubMed ID: 29801406
[TBL] [Abstract][Full Text] [Related]
4. EBV-positive HIV-associated diffuse large B cell lymphomas are characterized by JAK/STAT (STAT3) pathway mutations and unique clinicopathologic features.
Chapman JR; Bouska AC; Zhang W; Alderuccio JP; Lossos IS; Rimsza LM; Maguire A; Yi S; Chan WC; Vega F; Song JY
Br J Haematol; 2021 Sep; 194(5):870-878. PubMed ID: 34272731
[TBL] [Abstract][Full Text] [Related]
5. Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.
Staiger AM; Ziepert M; Horn H; Scott DW; Barth TFE; Bernd HW; Feller AC; Klapper W; Szczepanowski M; Hummel M; Stein H; Lenze D; Hansmann ML; Hartmann S; Möller P; Cogliatti S; Lenz G; Trümper L; Löffler M; Schmitz N; Pfreundschuh M; Rosenwald A; Ott G;
J Clin Oncol; 2017 Aug; 35(22):2515-2526. PubMed ID: 28525305
[TBL] [Abstract][Full Text] [Related]
6. Clinical Significance of
Ting CY; Chang KM; Kuan JW; Sathar J; Chew LP; Wong OJ; Yusuf Y; Wong L; Samsudin AT; Pana MNBM; Lee SK; Gopal NSR; Puri R; Ong TC; Bahari SK; Goh AS; Teoh CS
Int J Med Sci; 2019; 16(4):556-566. PubMed ID: 31171907
[No Abstract] [Full Text] [Related]
7. BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab.
Iqbal J; Meyer PN; Smith LM; Johnson NA; Vose JM; Greiner TC; Connors JM; Staudt LM; Rimsza L; Jaffe E; Rosenwald A; Ott G; Delabie J; Campo E; Braziel RM; Cook JR; Tubbs RR; Gascoyne RD; Armitage JO; Weisenburger DD; Chan WC
Clin Cancer Res; 2011 Dec; 17(24):7785-95. PubMed ID: 21933893
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical expression profile and prognosis in patients with diffuse large B-cell lymphoma with or without human immunodeficiency virus infection.
Xicoy B; Ribera JM; Mate JL; Tapia G; Morgades M; Navarro JT; Sanz C; Ariza A; Feliu E
Leuk Lymphoma; 2010 Nov; 51(11):2063-9. PubMed ID: 20929323
[TBL] [Abstract][Full Text] [Related]
9. Colorectal diffuse large B-cell lymphoma: molecular subclassification and prognostic significance of immunoglobulin gene translocation.
Hori Y; Yamamoto H; Nozaki Y; Torisu T; Fujiwara M; Taguchi K; Nishiyama K; Nakamura S; Kitazono T; Oda Y
Hum Pathol; 2020 Feb; 96():67-78. PubMed ID: 31734190
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of B-cell differentiation genes encoding proteins in diffuse large B-cell lymphoma and follicular lymphoma grade 3.
Borovecki A; Korać P; Nola M; Ivanković D; Jaksić B; Dominis M
Croat Med J; 2008 Oct; 49(5):625-35. PubMed ID: 18925696
[TBL] [Abstract][Full Text] [Related]
11. IRF8 is associated with germinal center B-cell-like type of diffuse large B-cell lymphoma and exceptionally involved in translocation t(14;16)(q32.33;q24.1).
Tinguely M; Thies S; Frigerio S; Reineke T; Korol D; Zimmermann DR
Leuk Lymphoma; 2014 Jan; 55(1):136-42. PubMed ID: 23573829
[TBL] [Abstract][Full Text] [Related]
12. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma.
Fu K; Weisenburger DD; Choi WW; Perry KD; Smith LM; Shi X; Hans CP; Greiner TC; Bierman PJ; Bociek RG; Armitage JO; Chan WC; Vose JM
J Clin Oncol; 2008 Oct; 26(28):4587-94. PubMed ID: 18662967
[TBL] [Abstract][Full Text] [Related]
13. HIV-infection impact on clinical-biological features and outcome of diffuse large B-cell lymphoma treated with R-CHOP in the combination antiretroviral therapy era.
Baptista MJ; Garcia O; Morgades M; Gonzalez-Barca E; Miralles P; Lopez-Guillermo A; Abella E; Moreno M; Sancho JM; Feliu E; Ribera JM; Navarro JT
AIDS; 2015 Apr; 29(7):811-8. PubMed ID: 25730510
[TBL] [Abstract][Full Text] [Related]
14. Primary diffuse large B-cell lymphoma of the oral cavity: germinal center classification.
Bhattacharyya I; Chehal HK; Cohen DM; Al-Quran SZ
Head Neck Pathol; 2010 Sep; 4(3):181-91. PubMed ID: 20533006
[TBL] [Abstract][Full Text] [Related]
15. BCL2 translocation defines a unique tumor subset within the germinal center B-cell-like diffuse large B-cell lymphoma.
Iqbal J; Sanger WG; Horsman DE; Rosenwald A; Pickering DL; Dave B; Dave S; Xiao L; Cao K; Zhu Q; Sherman S; Hans CP; Weisenburger DD; Greiner TC; Gascoyne RD; Ott G; Müller-Hermelink HK; Delabie J; Braziel RM; Jaffe ES; Campo E; Lynch JC; Connors JM; Vose JM; Armitage JO; Grogan TM; Staudt LM; Chan WC
Am J Pathol; 2004 Jul; 165(1):159-66. PubMed ID: 15215171
[TBL] [Abstract][Full Text] [Related]
16. Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma.
Xu-Monette ZY; Li L; Byrd JC; Jabbar KJ; Manyam GC; Maria de Winde C; van den Brand M; Tzankov A; Visco C; Wang J; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; Huh J; Ponzoni M; Ferreri AJ; Møller MB; Parsons BM; Winter JN; Wang M; Hagemeister FB; Piris MA; Han van Krieken J; Medeiros LJ; Li Y; van Spriel AB; Young KH
Blood; 2016 Dec; 128(26):3083-3100. PubMed ID: 27760757
[TBL] [Abstract][Full Text] [Related]
17. Diffuse Large B-Cell Lymphoma in Kenya: MYC, BCL2, and the Cell of Origin.
Wawire J; Sayed S; Moloo Z; Sohani AR
J Glob Oncol; 2019 May; 5():1-8. PubMed ID: 31045473
[TBL] [Abstract][Full Text] [Related]
18. Primary central nervous system diffuse large B-cell lymphoma shows an activated B-cell-like phenotype with co-expression of C-MYC, BCL-2, and BCL-6.
Li X; Huang Y; Bi C; Yuan J; He H; Zhang H; Yu Q; Fu K; Li D
Pathol Res Pract; 2017 Jun; 213(6):659-665. PubMed ID: 28552541
[TBL] [Abstract][Full Text] [Related]
19. Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study.
Visco C; Tzankov A; Xu-Monette ZY; Miranda RN; Tai YC; Li Y; Liu WM; d'Amore ES; Li Y; Montes-Moreno S; Dybkær K; Chiu A; Orazi A; Zu Y; Bhagat G; Wang HY; Dunphy CH; His ED; Zhao XF; Choi WW; Zhao X; van Krieken JH; Huang Q; Ai W; O'Neill S; Ponzoni M; Ferreri AJ; Kahl BS; Winter JN; Go RS; Dirnhofer S; Piris MA; Møller MB; Wu L; Medeiros LJ; Young KH
Haematologica; 2013 Feb; 98(2):255-63. PubMed ID: 22929980
[TBL] [Abstract][Full Text] [Related]
20. In situ BCL2 expression is an independent prognostic factor in HIV-associated DLBCL, a LYMPHOVIR cohort study.
Philippe L; Lancar R; Laurent C; Algarte-Genin M; Chassagne-Clément C; Fabiani B; Pierre Chenard M; Lazure T; Parrens M; Charlotte F; Delattre C; Gibault L; Capron F; Goubin-Versini I; Petitjean B; Boué F; Mounier N; Costello R; Costagliola D; Prevot S; Besson C;
Br J Haematol; 2020 Feb; 188(3):413-423. PubMed ID: 31468517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
